NCT04805671Phase 2, phase 3Terminated

Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-02-10Actual

Enrollment · participants399Actual

Source updated2024-02-06Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

COVID-19

Treatments or interventions studied

ADG20Drug
Normal salineDrug

Primary outcomes · main study measures

Read the study measures

measure: Incidence of COVID-19 Related Hospitalizations or All-cause Death; description: To evaluate the efficacy of ADG20 compared to placebo in the treatment of mild or moderate COVID-19 in participants at high risk of disease progression. Hospitalization is defined as ≥24 hours of acute care in a hospital or acute care facility (includes emergency rooms, intensive care units, acute care facilities created for COVID-19 pandemic hospitalization needs, or other acute care facilities). All-cause death is defined as death for any reason from Day 1 (postdose) through Day 29.; timeFrame: Through Day 29; measure: Incidence of Treatment-emergent Adverse Events; description: Proportion of participants with at least one treatment emergent AE; timeFrame: Through day 29; measure: Incidence of Solicited Injection Site Reactions; description: Proportion of participants with at least one solicited injection site reaction; timeFrame: Through Day 4; measure: Changes From Baseline in Clinical Laboratory Tests (ie, CBC With Differential, Serum Chemistry, Coagulation); description: Proportion of participants with a potentially clinically significant change from baseline in post-baseline laboratory parameters - data presented for any analyte with \>/= 2% in any arm; timeFrame: Through Day 29; measure: Changes From Baseline in Vital Signs (Body Temperature, Heart Rate, Respiration Rate, and Systolic and Diastolic Blood Pressure); description: Participants with Potentially Clinically Significant Changes (PCS) From Baseline in Vital Signs (Body Temperature, Heart Rate, Respiration Rate, and Systolic and Diastolic Blood Pressure) at Any Time Post-Baseline; timeFrame: Through Day 29

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history